• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $GRCE

    Grace Therapeutics Inc.

    Subscribe to $GRCE
    $GRCE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IPO Year:

    Exchange: NASDAQ

    Recent Analyst Ratings for Grace Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    5/2/2025$12.00Buy
    TD Cowen
    See more ratings

    Grace Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Kottayil George

      4 - Grace Therapeutics, Inc. (0001444192) (Issuer)

      5/13/25 5:21:16 PM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Davis A Brian

      4 - Grace Therapeutics, Inc. (0001444192) (Issuer)

      5/13/25 5:21:13 PM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Kavuru Vimal

      4 - Grace Therapeutics, Inc. (0001444192) (Issuer)

      5/13/25 5:21:11 PM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Neugeboren Edward

      4 - Grace Therapeutics, Inc. (0001444192) (Issuer)

      5/13/25 5:21:14 PM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Macdonald R. Loch

      4 - Grace Therapeutics, Inc. (0001444192) (Issuer)

      4/16/25 8:58:52 PM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by VP Program Management Kumar Amresh

      4 - Grace Therapeutics, Inc. (0001444192) (Issuer)

      4/16/25 8:58:53 PM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by VP Clinical Operations D'Andrea Carrie

      4 - Grace Therapeutics, Inc. (0001444192) (Issuer)

      4/16/25 8:58:47 PM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Principal Financial Officer Delaversano Robert J

      4 - Grace Therapeutics, Inc. (0001444192) (Issuer)

      4/16/25 8:58:50 PM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Kohli Prashant

      4 - Grace Therapeutics, Inc. (0001444192) (Issuer)

      4/16/25 8:58:49 PM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Grace Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104

      Submission Seeks Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Comprehensive Data Package Includes Positive Results from Phase 3 STRIVE-ON Safety Trial of GTx-104 Submission Has the Potential to Trigger Exercise of up to $7.6 million in Gross Proceeds from 2023 Financing Warrants Tied to FDA Acceptance of NDA for Review PRINCETON, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in ane

      6/25/25 8:00:00 AM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update

      Held Type C meeting with FDA on Planned New Drug Application (NDA) Submission, Including Clinical, Non-clinical, and Chemistry, Manufacturing, and Control (CMC) Requirements NDA On Track for Submission to FDA in First Half of Calendar 2025 NDA to be Supported by Data from Phase 3 STRIVE-ON Safety Trial, which Met Primary Endpoint and Provided Evidence of Clinical Benefit Compared to Orally Administered Nimodipine Secured Private Placement Financing of $15 Million in Upfront Gross Proceeds with the Potential to Receive up to an Additional $15 Million in Potential Warrant Exercise Proceeds for an Aggregate of Up to Approximately $30 Million in Potential Total Gross Proceeds PRINCETON, N.J.

      6/23/25 8:00:00 AM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Grace Therapeutics to Participate in the 2025 BIO International Conference

      PRINCETON, N.J., June 13, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that Chief Executive Officer Prashant Kohli will participate in the upcoming BIO 2025 International Conference, to be held in Boston, MA, June 16-19, 2025. Hosted by the Biotechnology Innovation Organization (BIO), the BIO International Convention is the world's largest and most influential biotechnology event

      6/13/25 8:00:00 AM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104

      PRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced details of the Company's Type C meeting with the U.S. Food and Drug Administration (FDA). The purpose of this meeting was to obtain FDA feedback on the completed Phase 3 STRIVE-ON safety trial of GTx-104 and its planned New Drug Application (NDA) submission including clinical, non-clinical, and chemistry, manu

      4/9/25 8:00:00 AM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

      BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025 (the "Effective Date"). In addition, Matthew Wikler, M.D., and Natasha Giordano stepped down from the Board on the Effective Date. "We are thrilled to announce the addition of Keith and Edward to our Board," stated Jerome D. Jabbour, Chief Executive Officer of Matinas. "Their deep industry experience, leadership expertise, and capital markets acumen will be of great value as we move the company forward into a new era continu

      3/11/25 7:00:00 AM ET
      $GRCE
      $MTNB
      $ONVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

      PRINCETON, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) formerly Acasti Pharma Inc. (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that Chief Executive Officer Prashant Kohli will participate in the upcoming TD Cowen 45th Annual Health Care Conference, to be held in Boston, MA, March 3-5, 2025. TD Cowen 45th Annual Health Care ConferenceFormat: Presentation and one-on-one investor meetingsDate: March 4, 2025Tim

      2/25/25 8:00:00 AM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update

      Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug Application (NDA) Submission Anticipated First Half of Calendar 2025 Secured Private Placement Financing of $15 Million in Upfront Gross Proceeds with the Potential to Receive up to an Additional $15 Million in Potential Warrant Exercise Proceeds for an Aggregate of Up to Approximately $30 Million in Potential Total Gross Proceeds PRINCETON, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) formerly Acasti Pharma Inc. (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104,

      2/13/25 8:00:00 AM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Grace Therapeutics Announces Private Placement Financing of up to $30 Million

      Financing led by Nantahala Capital and ADAR1 Partners, LP with participation from new and existing healthcare-focused institutional investors $15 million in upfront gross proceeds with the potential to receive up to an additional $15 million in potential warrant exercise proceeds for an aggregate of up to approximately $30 million in potential total gross proceeds PRINCETON, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) --  Grace Therapeutics, Inc. (NASDAQ:GRCE), formerly Acasti Pharma Inc. (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unme

      2/10/25 8:05:00 AM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH

      Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine New Drug Application (NDA) Submission Expected in the First Half of 2025 PRINCETON, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE), formerly Acasti Pharma Inc. (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal Subarachnoid Hemorrhage (aSAH) patients, today announced that its Phase 3 STRIVE-ON safety trial (the STRIVE-ON trial–NCT05995405) met its pr

      2/10/25 8:01:00 AM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Grace Therapeutics to Participate in Upcoming Investor Events January 2025

      PRINCETON, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) formerly Acasti Pharma Inc. (NASDAQ:ACST) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs, today announced that Chief Executive Officer Prashant Kohli will participate the following investor and industry networking events during the month of January 2025. 14th Annual LifeSci Partners Corporate Access Event – (January 13, 2025) BIO One-on-One Partnering™ – (Ja

      1/7/25 8:00:00 AM ET
      $ACST
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Grace Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen initiated coverage on Grace Therapeutics with a new price target

      TD Cowen initiated coverage of Grace Therapeutics with a rating of Buy and set a new price target of $12.00

      5/2/25 8:14:37 AM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Grace Therapeutics Inc. SEC Filings

    See more
    • Grace Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Grace Therapeutics, Inc. (0001444192) (Filer)

      6/25/25 8:19:04 AM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Grace Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Grace Therapeutics, Inc. (0001444192) (Filer)

      6/23/25 8:00:43 AM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Grace Therapeutics Inc.

      10-K - Grace Therapeutics, Inc. (0001444192) (Filer)

      6/23/25 7:43:32 AM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Grace Therapeutics Inc.

      SCHEDULE 13G - Grace Therapeutics, Inc. (0001444192) (Subject)

      5/15/25 4:46:05 PM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Grace Therapeutics Inc.

      SCHEDULE 13G/A - Grace Therapeutics, Inc. (0001444192) (Subject)

      5/8/25 7:51:32 AM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Grace Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Grace Therapeutics, Inc. (0001444192) (Filer)

      4/9/25 8:00:28 AM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Grace Therapeutics Inc.

      EFFECT - Grace Therapeutics, Inc. (0001444192) (Filer)

      3/14/25 12:15:14 AM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-3 filed by Grace Therapeutics Inc.

      S-3 - Grace Therapeutics, Inc. (0001444192) (Filer)

      3/10/25 7:58:09 AM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Grace Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Grace Therapeutics, Inc. (0001444192) (Filer)

      3/3/25 8:00:39 AM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form D filed by Grace Therapeutics Inc.

      D - Grace Therapeutics, Inc. (0001444192) (Filer)

      2/25/25 3:05:03 PM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Grace Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

      BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025 (the "Effective Date"). In addition, Matthew Wikler, M.D., and Natasha Giordano stepped down from the Board on the Effective Date. "We are thrilled to announce the addition of Keith and Edward to our Board," stated Jerome D. Jabbour, Chief Executive Officer of Matinas. "Their deep industry experience, leadership expertise, and capital markets acumen will be of great value as we move the company forward into a new era continu

      3/11/25 7:00:00 AM ET
      $GRCE
      $MTNB
      $ONVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    Grace Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Grace Therapeutics Inc.

      SC 13G/A - Grace Therapeutics, Inc. (0001444192) (Subject)

      11/14/24 4:40:44 PM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Grace Therapeutics Inc.

      SC 13G/A - Grace Therapeutics, Inc. (0001444192) (Subject)

      11/14/24 11:58:16 AM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care